# MRNA vs RPRX: Fair Value Comparison

Source: https://www.equity-rank.com/compare/mrna-vs-rprx

Moderna Inc vs. Royalty Pharma Plc · Biotechnology

MRNA's model fair value sits 95.1% below its current price; RPRX's model fair value sits 34.5% below its current price. Of the two, RPRX trades further below its model estimate. Model estimates under stated assumptions. Data as of 2026-11-09.

|  | [MRNA](https://www.equity-rank.com/stocks/MRNA) | [RPRX](https://www.equity-rank.com/stocks/RPRX) |
| --- | --- | --- |
| Price | $269.00 | $68.77 |
| Model fair value (multi-method blend) | $13.09 | $45.04 |
| Model fair value differential | -95.1% | -34.5% |
| Methods with a model value above price | 2 of 2 | 6 of 8 |
| Fundamental strength | C- | B |
| Next earnings report | — | — |

Differential = model fair value versus the current price; positive means the price sits below the model estimate.

## More comparisons

[VRTX vs MRNA](https://www.equity-rank.com/compare/vrtx-vs-mrna) · [MRNA vs REGN](https://www.equity-rank.com/compare/mrna-vs-regn) · [VRTX vs RPRX](https://www.equity-rank.com/compare/vrtx-vs-rprx) · [REGN vs RPRX](https://www.equity-rank.com/compare/regn-vs-rprx) · [All Biotechnology stocks](https://www.equity-rank.com/stocks/industry/biotechnology) · [Compare any two stocks](https://www.equity-rank.com/compare)

---

Fair value is a model estimate under stated assumptions — not a price target, not a prediction, and not a recommendation. This page is research information, not investment advice. Equity Rank is not a registered investment adviser.